Australian-based pharmaceutical company AusCann Group has successfully completed the first clinical study of its orally administered THC and CBD combination using the company’s proprietary Neuvisa platform of self-emulsifying powder in hard-shell capsules.

The randomised, open-label, cross-over phase one study evaluated the pharmacokinetics and safety of a single dose in fed healthy volunteers.

The study was managed by Melbourne-based contract research organisation, Nucleus Network, enrolling 28 volunteers with 25 completing the study.

AusCann’s chief medical advisor, Dr Marc Russo, said that the hard-shell capsule showed a lower peak concentration than the oil-based comparator.

“Having a pharmacokinetic curve that is optimised to an appropriate peak level with a more sustained duration, as was evident from this study with AusCann’s capsules, should translate to improved outcomes and reduced side effects for patients,” he added.